Skip to main content
. 2022 Feb 8;10:712484. doi: 10.3389/fcell.2022.712484

FIGURE 1.

FIGURE 1

RAS mutations in patients with newly diagnosed and relapsed ALL. (A) Identification of HRAS, KRAS and NRAS mutations in patients with newly diagnosed and relapsed ALL enrolled onto CCCG-ALL-2015 clinical trial at Guangzhou Women and Children’s Medical Center. (B) RAS mutations frequency between newly diagnosed (N = 333) and relapsed (N = 18) cases. (C) RAS mutations frequency between diagnostic T-ALL and B-ALL. (D) NRAS mutations frequency including G12, G13, G60, Q61, Y64 and A146 residues in this study cohort. (E) NRAS mutation profile from our study cohort (upper panel) and PCGP study cohort. NRAS mutations spanned the full length of the gene (upper panel, our study cohort; lower panel, PCGP; red line, newly diagnosed ALL; black line, relapsed ALL; solid red circle, missense mutations; solid green circle, insertion mutations; number in this circle represents case number). McNemar chi-square test was performed to compare the frequency of KRAS, NRAS, and HRAS. p < 0.05 (*, <0.05; **, <0.01) was considered statistically significant.